{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T20:17:53Z","timestamp":1717359473934},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2010,7,15]],"date-time":"2010-07-15T00:00:00Z","timestamp":1279152000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hautarzt"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1007\/s00105-010-1943-6","type":"journal-article","created":{"date-parts":[[2010,7,13]],"date-time":"2010-07-13T09:48:51Z","timestamp":1279014531000},"page":"654-661","source":"Crossref","is-referenced-by-count":8,"title":["Therapie mit Inhibitoren des epidermalen Wachstumsfaktorrezeptors"],"prefix":"10.1007","volume":"61","author":[{"given":"P.A.","family":"Gerber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.A.","family":"Buhren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"K\u00fcrle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Homey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,7,15]]},"reference":[{"key":"1943_CR1","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2005.10.010","volume":"55","author":"Agero","year":"2006","unstructured":"Agero Al, Dusza SW, Benvenuto-Andrade C et al (2006) Dermatologic side effects associated with the epidermal growth factor receptor inhibitors. J Am Acad Dermatol 55:657\u2013670","journal-title":"J Am Acad Dermatol"},{"key":"1943_CR2","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/nrd842","volume":"1","author":"Atkins","year":"2002","unstructured":"Atkins JH, Gershell LJ (2002) Selective anticancer drugs. Nat Rev Drug Discov 1:491\u2013492","journal-title":"Nat Rev Drug Discov"},{"key":"1943_CR3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/annonc\/mdm400","volume":"19","author":"Bernier","year":"2008","unstructured":"Bernier J, Bonner J, Vermorken JB et al (2008) Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck. Ann Oncol 19:142\u2013149","journal-title":"Ann Oncol"},{"key":"1943_CR4","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00066-008-1829-z","volume":"184","author":"Bolke","year":"2008","unstructured":"Bolke E, Gerber PA, Lammering G et al (2008) Development and management of severe cutaneous side effects in head-and-neck cancer patients during concurrent radiotherapy and cetuximab. Strahlenther Onkol 184:105\u2013110","journal-title":"Strahlenther Onkol"},{"key":"1943_CR5","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1056\/NEJMc076359","volume":"357","author":"Bonner","year":"2007","unstructured":"Bonner JA, Ang K (2007) More on severe cutaneous reaction with radiotherapy and cetuximab. N Engl J Med 357:1872\u20131873; author reply 1873","journal-title":"N Engl J Med"},{"key":"1943_CR6","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","volume":"354","author":"Bonner","year":"2006","unstructured":"Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567\u2013578","journal-title":"N Engl J Med"},{"key":"1943_CR7","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1159\/000112795","volume":"72","author":"Boone","year":"2007","unstructured":"Boone Sl, Rademaker A, Liu D et al (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72:152\u2013159","journal-title":"Oncology"},{"key":"1943_CR8","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMc071075","volume":"357","author":"Budach","year":"2007","unstructured":"Budach W, Bolke E, Homey B (2007) Severe cutaneous reaction during radiation therapy with concurrent cetuximab. N Engl J Med 357:514\u2013515","journal-title":"N Engl J Med"},{"key":"1943_CR9","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1046\/j.1365-2133.2001.04226.x","volume":"144","author":"Busam","year":"2001","unstructured":"Busam KJ, Capodieci P, Motzer R et al (2001) Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 144:1169\u20131176","journal-title":"Br J Dermatol"},{"key":"1943_CR10","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","volume":"358","author":"Ciardiello","year":"2008","unstructured":"Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358:1160\u20131174","journal-title":"N Engl J Med"},{"key":"1943_CR11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337\u2013345","journal-title":"N Engl J Med"},{"key":"1943_CR12","doi-asserted-by":"crossref","unstructured":"Eilers RE Jr, Gandhi M, Patel JD et al (n d) Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst 102:47\u201353","DOI":"10.1093\/jnci\/djp439"},{"key":"1943_CR13","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nrclinonc.2009.16","volume":"6","author":"Eng","year":"2009","unstructured":"Eng C (2009) Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol 6:207\u2013218","journal-title":"Nat Rev Clin Oncol"},{"key":"1943_CR14","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaad.2006.09.013","volume":"56","author":"Fox","year":"2007","unstructured":"Fox LP (2007) Nail toxicity associated with epidermal growth factor receptor inhibitor therapy. J Am Acad Dermatol 56:460\u2013465","journal-title":"J Am Acad Dermatol"},{"key":"1943_CR15","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1200\/JCO.2007.16.0077","volume":"26","author":"Gerber","year":"2008","unstructured":"Gerber PA, Enderlein E, Homey B (2008) The Koebner-phenomenon in epidermal growth factor receptor inhibitor-induced cutaneous adverse effects. J Clin Oncol 26:2790\u20132792","journal-title":"J Clin Oncol"},{"key":"1943_CR16","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2007.12.8330","volume":"25","author":"Gerber","year":"2007","unstructured":"Gerber PA, Enderlein E, Homey B et al (2007) Radiation-induced prevention of erlotinib-induced skin rash is transient: a new aspect toward the understanding of epidermal growth factor receptor inhibitor associated cutaneous adverse effects. J Clin Oncol 25:4697\u20134698; author reply 4698\u20134699","journal-title":"J Clin Oncol"},{"key":"1943_CR17","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1056\/NEJMicm073144","volume":"358","author":"Gerber","year":"2008","unstructured":"Gerber PA, Homey B (2008) Images in clinical medicine. Erlotinib-induced hair alterations. N Engl J Med 358:1175","journal-title":"N Engl J Med"},{"key":"1943_CR18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.radonc.2008.09.007","volume":"90","author":"Giro","year":"2009","unstructured":"Giro C, Berger B, Bolke E et al (2009) High rate of severe radiation dermatitis during radiation therapy with concurrent cetuximab in head and neck cancer: results of a survey in EORTC institutes. Radiother Oncol 90:166\u2013171","journal-title":"Radiother Oncol"},{"key":"1943_CR19","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1634\/theoncologist.12-5-577","volume":"12","author":"Giusti","year":"2007","unstructured":"Giusti RM, Shastri KA, Cohen MH et al (2007) FDA drug approval summary: panitumumab (Vectibix). Oncologist 12:577\u2013583","journal-title":"Oncologist"},{"key":"1943_CR20","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.jaad.2005.12.016","volume":"55","author":"Graves","year":"2006","unstructured":"Graves JE, Jones BF, Lind AC et al (2006) Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib. J Am Acad Dermatol 55:349\u2013353","journal-title":"J Am Acad Dermatol"},{"key":"1943_CR21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3816\/CLC.2008.n.010","volume":"9","author":"Grenader","year":"2008","unstructured":"Grenader T, Gipps M, Goldberg A (2008) Staphylococcus aureus bacteremia secondary to severe erlotinib skin toxicity. Clin Lung Cancer 9:59\u201360","journal-title":"Clin Lung Cancer"},{"key":"1943_CR22","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1111\/j.1365-2133.2004.06026.x","volume":"151","author":"Jacot","year":"2004","unstructured":"Jacot W, Bessis D, Jorda E et al (2004) Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 151:238\u2013241","journal-title":"Br J Dermatol"},{"key":"1943_CR23","first-page":"46","volume":"33","author":"Kardaun","year":"2008","unstructured":"Kardaun SH, Van Duinen KF (2008) Erlotinib-induced florid acneiform rash complicated by extensive impetiginization. Clin Exp Dermatol 33:46\u201349","journal-title":"Clin Exp Dermatol"},{"key":"1943_CR24","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1016\/S0140-6736(08)61758-4","volume":"372","author":"Kim","year":"2008","unstructured":"Kim ES, Hirsh V, Mok T et al (2008) Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 372:1809\u20131818","journal-title":"Lancet"},{"key":"1943_CR25","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1056\/NEJMra044389","volume":"353","author":"Krause","year":"2005","unstructured":"Krause DS, Van Etten RA (2005) Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172\u2013187","journal-title":"N Engl J Med"},{"key":"1943_CR26","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/nrc1970","volume":"6","author":"Lacouture","year":"2006","unstructured":"Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803\u2013812","journal-title":"Nat Rev Cancer"},{"key":"1943_CR27","doi-asserted-by":"crossref","unstructured":"Lacouture ME, Mitchell EP, Piperdi B et al (n d) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351\u20131357","DOI":"10.1200\/JCO.2008.21.7828"},{"key":"1943_CR28","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11523-009-0114-0","volume":"4","author":"Li","year":"2009","unstructured":"Li T, Perez-Soler R (2009) Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol 4:107\u2013119","journal-title":"Target Oncol"},{"key":"1943_CR29","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1159\/000279388","volume":"77","author":"Lurje","year":"2009","unstructured":"Lurje G, Lenz HJ (2009) EGFR signaling and drug discovery. Oncology 77:400\u2013410","journal-title":"Oncology"},{"key":"1943_CR30","doi-asserted-by":"crossref","first-page":"e28","DOI":"10.1200\/JCO.2005.05.1631","volume":"24","author":"Mitra","year":"2006","unstructured":"Mitra SS, Simcock R (2006) Erlotinib induced skin rash spares skin in previous radiotherapy field. J Clin Oncol 24:e28\u2013e29","journal-title":"J Clin Oncol"},{"key":"1943_CR31","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960\u20131966","journal-title":"J Clin Oncol"},{"key":"1943_CR32","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1111\/j.1600-0560.2009.01275.x","volume":"36","author":"Pongpudpunth","year":"2009","unstructured":"Pongpudpunth M, Demierre MF, Goldberg LJ (2009) A case report of inflammatory nonscarring alopecia associated with the epidermal growth factor receptor inhibitor erlotinib. J Cutan Pathol 36:1303\u20131307","journal-title":"J Cutan Pathol"},{"key":"1943_CR33","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3816\/CLC.2009.n.004","volume":"10","author":"Ricciardi","year":"2009","unstructured":"Ricciardi S, Tomao S, De Marinis F (2009) Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 10:28\u201335","journal-title":"Clin Lung Cancer"},{"key":"1943_CR34","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/1040-8428(94)00144-I","volume":"19","author":"Salomon","year":"1995","unstructured":"Salomon DS, Brandt R, Ciardiello F et al (1995) Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183\u2013232","journal-title":"Crit Rev Oncol Hematol"},{"key":"1943_CR35","doi-asserted-by":"crossref","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","volume":"25","author":"Scope","year":"2007","unstructured":"Scope A, Agero Al, Dusza SW et al (2007) Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25:5390\u20135396","journal-title":"J Clin Oncol"},{"key":"1943_CR36","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0959-8049(09)70044-9","volume":"45","author":"Segaert","year":"2009","unstructured":"Segaert S, Chiritescu G, Lemmens L et al (2009) Skin toxicities of targeted therapies. Eur J Cancer 45(Suppl 1):295\u2013308","journal-title":"Eur J Cancer"},{"key":"1943_CR37","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1093\/annonc\/mdi279","volume":"16","author":"Segaert","year":"2005","unstructured":"Segaert S, Van Cutsem E (2005) Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 16:1425\u20131433","journal-title":"Ann Oncol"},{"key":"1943_CR38","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa050753","volume":"353","author":"Shepherd","year":"2005","unstructured":"Shepherd FA, Rodrigues Pereira J, Ciuleanu T et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123\u2013132","journal-title":"N Engl J Med"},{"key":"1943_CR39","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1038\/sj.bjc.6604053","volume":"97","author":"Siena","year":"2007","unstructured":"Siena S, Peeters M, Van Cutsem E et al (2007) Association of progression-free survival with patient-reported outcomes and survival: results from a randomised phase 3 trial of panitumumab. Br J Cancer 97:1469\u20131474","journal-title":"Br J Cancer"},{"key":"1943_CR40","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1634\/theoncologist.11-9-1010","volume":"11","author":"Van","year":"2006","unstructured":"Van Cutsem E (2006) Challenges in the use of epidermal growth factor receptor inhibitors in colorectal cancer. Oncologist 11:1010\u20131017","journal-title":"Oncologist"},{"key":"1943_CR41","doi-asserted-by":"crossref","first-page":"4602","DOI":"10.1200\/JCO.2005.07.757","volume":"23","author":"Von","year":"2005","unstructured":"Von Der Maase H, Sengelov L, Roberts JT et al (2005) Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 23:4602\u20134608","journal-title":"J Clin Oncol"},{"key":"1943_CR42","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1158\/1078-0432.CCR-06-2610","volume":"13","author":"Wacker","year":"2007","unstructured":"Wacker B, Nagrani T, Weinberg J et al (2007) Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913\u20133921","journal-title":"Clin Cancer Res"},{"key":"1943_CR43","doi-asserted-by":"crossref","unstructured":"Wollenberg A, Kroth J, Hauschild A et al (n d) Cutaneous side effects of EGFR inhibitors \u2013 appearance and management. Dtsch Med Wochenschr 135:149\u2013154","DOI":"10.1055\/s-0029-1244831"},{"key":"1943_CR44","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1111\/j.1600-0625.2008.00715.x","volume":"17","author":"Wollenberg","year":"2008","unstructured":"Wollenberg A, Moosmann N, Klein E et al (2008) A tool for scoring of acneiform skin eruptions induced by EGF receptor inhibition. Exp Dermatol 17:790\u2013792","journal-title":"Exp Dermatol"},{"key":"1943_CR45","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s00105-006-1256-y","volume":"58","author":"Wollenberg","year":"2007","unstructured":"Wollenberg A, Moosmann N, Kroth J et al (2007) Therapy of severe cetuximab-induced acneiform eruptions with oral retinoid, topical antibiotic and topical corticosteroid. Hautarzt 58:615\u2013618","journal-title":"Hautarzt"}],"container-title":["Der Hautarzt"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-010-1943-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00105-010-1943-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00105-010-1943-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T23:37:47Z","timestamp":1558568267000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00105-010-1943-6"}},"subtitle":["Spektrum kutaner Nebenwirkungen"],"short-title":[],"issued":{"date-parts":[[2010,7,15]]},"references-count":45,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["1943"],"URL":"https:\/\/doi.org\/10.1007\/s00105-010-1943-6","relation":{},"ISSN":["0017-8470","1432-1173"],"issn-type":[{"value":"0017-8470","type":"print"},{"value":"1432-1173","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,15]]}}}